Lilly Announces Initiation of the Observational Survey of the Epidemiology, Treatment and Care of Migraine (OVERCOME) to Advance Understanding of Burden, Impact and Epidemiology of Migraine
"Though more than 36 million Americans are living with migraine, there is a lack of recognition and appreciation for the burden and impact of this neurobiological disease," said
The OVERCOME study is a two-year, multi-wave prospective, web-based patient survey that leverages learnings from the American Migraine Prevalence and Prevention Study (AMPP), the seminal, longitudinal, population-based migraine study initiated in 2004. Baseline data from OVERCOME will be available in 2019, and data collection on the study is expected to end in 2022.
"This type of research – and at this scale – is crucial to our continued understanding of migraine and to inform clinical practice and patient access as treatment evolves," said the chair of the study's
The OVERCOME study is being conducted by
Dawn C. Buse, Ph.D., clinical professor of Neurology at the Albert Einstein College of Medicine, assistant professor in the Clinical Health Psychology Doctoral Program of the Ferkauf Graduate School of Psychology, Yeshiva University Michael L. Reed, Ph.D., managing director of Vedanta Research Richard B. Lipton, M.D., professor of Neurology, professor of Epidemiology and Population Healthand director, Montefiore Headache Center, Albert Einstein College Of Medicine Robert E. Shapiro, M.D., Ph.D., professor of Neurological Sciences, Robert Larner, M.D., College of Medicineat The University of Vermont Sait Ashina, M.D., director of Comprehensive Headache Center, Departments of Neurology and Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School
About the OVERCOME Study
The OVERCOME study will enroll two 20,000-person population samples to be followed longitudinally for two years. The first population sample will begin enrollment in
About Lilly's Commitment to Headache Disorders
For more than 25 years, Lilly has been committed to helping people suffering from headache disorders, investigating more than a dozen different compounds for the treatment of migraine, cluster headache and other disabling headache disorders. These research programs have accelerated the understanding of these neurobiological diseases and furthered the advancement of Lilly's comprehensive late-stage development programs for the prevention of migraine and cluster headache, and for the acute treatment of migraine. Our goal is to make life better for people with headache disorders by offering comprehensive solutions to prevent or stop these disabling diseases. The combined clinical, academic and professional experience of our experts helps us to build our research portfolio, identify challenges for healthcare providers and pinpoint the needs of patients living with migraine and cluster headache.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels. P-LLY
Refer to: Jen Dial; email@example.com; 317-220-1172 (Lilly Bio-Medicines)
View original content with multimedia:http://www.prnewswire.com/news-releases/lilly-announces-initiation-of-the-observational-survey-of-the-epidemiology-treatment-and-care-of-migraine-overcome-to-advance-understanding-of-burden-impact-and-epidemiology-of-migraine-300674138.html